PMID- 35511691
OWN - NLM
STAT- MEDLINE
DCOM- 20220908
LR  - 20221206
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 158
IP  - 3
DP  - 2022 Sep 2
TI  - A Combined Biomarker of Bright CD38 and MYC >/=55% Is Highly Predictive of 
      Double-/Triple-Hit High-Grade B-Cell Lymphoma.
PG  - 338-344
LID - 10.1093/ajcp/aqac047 [doi]
AB  - OBJECTIVES: Diagnosis of high-grade B-cell lymphoma with MYC and BCL2 or BCL6 
      rearrangements (double-/triple-hit lymphoma [DTHL]) appears to mandate 
      fluorescence in situ hybridization (FISH) testing for all large B-cell lymphoma 
      (LBCL). Given the low incidence of DTHL, we aimed to identify flow cytometry (FC) 
      and immunohistochemistry (IHC) features of DTHL that could be used to develop an 
      optimal screening strategy. This combined FC-IHC approach has not yet been 
      studied. METHODS: We compared features of 40 cases of DTHL and 39 cases of 
      diffuse LBCL (DLBCL) without MYC rearrangement. RESULTS: Bright CD38 expression 
      (CD38bright) by FC, high MYC expression (>/=55%), and double-expressor phenotype by 
      IHC were significantly associated with DTHL. The biomarker combining FC and IHC, 
      CD38bright and/or MYC >/=55%, was superior to FC and IHC markers alone in 
      predicting DTHL. Restricting FISH testing to approximately 25% of LBCL based on 
      CD38brightand/or MYC >/=55% would detect approximately 95% of DTHL-BCL2 and 
      approximately 75% of DHL-BCL6. CONCLUSIONS: Our study demonstrated that the novel 
      biomarker of CD38bright and/or MYC >/=55% is highly predictive of DTHL. Awareness 
      of the advantages and limitations of this screening strategy would facilitate 
      development of a rational diagnostic workflow to provide high-quality patient 
      care.
CI  - (c) The Author(s) 2022. Published by Oxford University Press on behalf of American 
      Society for Clinical Pathology. All rights reserved. For permissions, please 
      e-mail: journals.permissions@oup.com.
FAU - Alsuwaidan, Abdullah
AU  - Alsuwaidan A
AD  - Department of Pathology, University of Texas Southwestern Medical Center, Dallas, 
      TX, USA.
FAU - Koduru, Prasad
AU  - Koduru P
AD  - Department of Pathology, University of Texas Southwestern Medical Center, Dallas, 
      TX, USA.
FAU - Fuda, Franklin
AU  - Fuda F
AD  - Department of Pathology, University of Texas Southwestern Medical Center, Dallas, 
      TX, USA.
FAU - Manuel Jaso, Jesse
AU  - Manuel Jaso J
AD  - Department of Pathology, University of Texas Southwestern Medical Center, Dallas, 
      TX, USA.
FAU - Chen, Mingyi
AU  - Chen M
AD  - Department of Pathology, University of Texas Southwestern Medical Center, Dallas, 
      TX, USA.
FAU - Rosado, Flavia
AU  - Rosado F
AD  - Department of Pathology, University of Texas Southwestern Medical Center, Dallas, 
      TX, USA.
FAU - Luu, Hung S
AU  - Luu HS
AD  - Department of Pathology, University of Texas Southwestern Medical Center, Dallas, 
      TX, USA.
FAU - Sweed, Nathan
AU  - Sweed N
AD  - Department of Pathology, University of Texas Southwestern Medical Center, Dallas, 
      TX, USA.
FAU - Garcia, Rolando
AU  - Garcia R
AD  - Department of Pathology, University of Texas Southwestern Medical Center, Dallas, 
      TX, USA.
FAU - Doucet, Meggie
AU  - Doucet M
AD  - Department of Pathology, University of Texas Southwestern Medical Center, Dallas, 
      TX, USA.
FAU - Desai, Neil B
AU  - Desai NB
AD  - Department of Radiation Oncology, University of Texas Southwestern Medical 
      Center, Dallas, TX, USA.
FAU - Kumar, Kiran A
AU  - Kumar KA
AD  - Department of Radiation Oncology, University of Texas Southwestern Medical 
      Center, Dallas, TX, USA.
FAU - Awan, Farrukh T
AU  - Awan FT
AD  - Internal Medicine/Division of Hematologic Malignancies and Stem Cell 
      Transplantation, University of Texas Southwestern Medical Center, Dallas, TX, 
      USA.
FAU - Ramakrishnan Geethakumari, Praveen
AU  - Ramakrishnan Geethakumari P
AD  - Internal Medicine/Division of Hematologic Malignancies and Stem Cell 
      Transplantation, University of Texas Southwestern Medical Center, Dallas, TX, 
      USA.
FAU - Chen, Weina
AU  - Chen W
AUID- ORCID: 0000-0001-5638-4371
AD  - Department of Pathology, University of Texas Southwestern Medical Center, Dallas, 
      TX, USA.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MYC protein, human)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - EC 3.2.2.5 (CD38 protein, human)
RN  - EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
SB  - IM
MH  - ADP-ribosyl Cyclase 1/*blood
MH  - Biomarkers, Tumor/genetics
MH  - Gene Rearrangement
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Lymphoma, Large B-Cell, Diffuse/diagnosis/genetics/pathology
MH  - Membrane Glycoproteins/*blood
MH  - Proto-Oncogene Proteins c-bcl-2/genetics
MH  - Proto-Oncogene Proteins c-bcl-6/genetics
MH  - Proto-Oncogene Proteins c-myc/*blood/genetics
OTO - NOTNLM
OT  - CD38
OT  - Double-/triple-hit lymphoma
OT  - Flow cytometry
OT  - High-grade B-cell lymphoma
OT  - Immunohistochemistry
OT  - MYC
EDAT- 2022/05/06 06:00
MHDA- 2022/09/09 06:00
CRDT- 2022/05/05 13:13
PHST- 2021/11/29 00:00 [received]
PHST- 2022/03/24 00:00 [accepted]
PHST- 2022/05/06 06:00 [pubmed]
PHST- 2022/09/09 06:00 [medline]
PHST- 2022/05/05 13:13 [entrez]
AID - 6577222 [pii]
AID - 10.1093/ajcp/aqac047 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2022 Sep 2;158(3):338-344. doi: 10.1093/ajcp/aqac047.